Increased serum tumor necrosis factor α levels in patients with lenalidomide-induced hypothyroidism

Wade T Iams; Megan L Hames; Judy P Tsai; Kimberly B Dahlman; Mahsa S Talbott; Kristy L Richards; Nishitha M Reddy

doi:10.1016/j.exphem.2014.10.009

Increased serum tumor necrosis factor α levels in patients with lenalidomide-induced hypothyroidism

Exp Hematol. 2015 Feb;43(2):74-8. doi: 10.1016/j.exphem.2014.10.009. Epub 2014 Oct 28.

Authors

Wade T Iams¹, Megan L Hames², Judy P Tsai³, Kimberly B Dahlman⁴, Mahsa S Talbott², Kristy L Richards⁵, Nishitha M Reddy⁶

Affiliations

¹ Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
² Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA.
³ Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
⁴ Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, TN, USA.
⁵ Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.
⁶ Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: [email protected].

Abstract

As the use of lenalidomide expands, the poorly understood phenomenon of lenalidomide-induced thyroid abnormalities will increase. In this study, we compared rates of therapy-induced hypothyroidism in 329 patients with diffuse large B-cell lymphoma (DLBCL) treated with conventional chemotherapy (DLBCL-c) or conventional chemotherapy plus lenalidomide (DLBCL-len). We measured serum levels of tumor necrosis factor α, interferon gamma, interleukin 6, interleukin 12, and interleukin 15 before and after treatment. We found a significantly higher rate of therapy-induced hypothyroidism in the DLBCL-len group (25.8% vs. 1.3%), and we found a statistically significant increase in serum tumor necrosis factor α in patients with lenalidomide-induced hypothyroidism.

Publication types

Clinical Trial, Phase II
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Murine-Derived / administration & dosage
Antineoplastic Agents / administration & dosage
Antineoplastic Combined Chemotherapy Protocols*
Female
Humans
Hypothyroidism / blood
Hypothyroidism / chemically induced
Hypothyroidism / pathology*
Immunologic Factors / adverse effects*
Interferon-gamma / blood
Interleukin-12 / blood
Interleukin-15 / blood
Interleukin-6 / blood
Lenalidomide
Lymphoma, Large B-Cell, Diffuse / blood
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Lymphoma, Large B-Cell, Diffuse / pathology
Male
Middle Aged
Rituximab
Severity of Illness Index
Thalidomide / adverse effects
Thalidomide / analogs & derivatives*
Tumor Necrosis Factor-alpha / blood*

Substances

Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents
IL15 protein, human
IL6 protein, human
Immunologic Factors
Interleukin-15
Interleukin-6
Tumor Necrosis Factor-alpha
Interleukin-12
Rituximab
Thalidomide
Interferon-gamma
Lenalidomide

Abstract

Publication types

MeSH terms

Substances

Grants and funding